[Sclerotherapy with 75% ethanol in the control of hemorrhage caused by peptic ulcer disease]. / Escleroterapia con etanol al 75% en el control de la hemorragia por enfermedad ulcero-péptica.

We present our experience using ethanol as sclerosant of non-variceal bleeding lesions of the upper digestive tract and the result of its hemostatic effect when compared with patients who received conventional medical treatment. Since January 1989, 48 patients admitted with active bleeding or signs of high risk for rebleeding (clot or visible vessel) were submitted to sclerosis. The historic control group included patients admitted before 1989, being both groups comparable in clinical and endoscopic characteristics. Surgery was performed in 5 cases of the sclerosis group (10.4%) versus 14 of the control group (37.8%). Five of the patients in the sclerotherapy group died, one of them due to upper G.I. bleeding as the primary cause. We dit not observe a statistically significant difference in hospital stay, transfusion requirements or mortality. There were no complications as a result of the method. Sclerotherapy was not immediately effective in 2 patients; three patients who rebled were subject to new sclerosis, which was effective in controlling bleeding in two of them. In conclusion, sclerosis is a safe and effective method to achieve hemostasis, diminishing the re-bleeding and the need for surgery in cases of digestive bleeding due to peptic ulcer disease. Future studies using larger samples could show decrease in mortality.

[Clinical and prognostic factors of mortality in upper digestive hemorrhage]. / Factores clínicos pronósticos de mortalidad en hemorragia digestiva superior.

In order to investigate prognostic factors we prospectively followed 741 patients with upper gastrointestinal bleeding (UGIB). Eleven variables were identified with mortality predictive value. Hematemesis, age of 50 y/o, more than 120 heart beat/minute, 3 or more units of pack red blood cells, esophageal varices, cirrhotic liver and renal failure had independent predictive value. Our findings could help to identify high risk patients.

[Upper gastrointestinal hemorrhage. Prospective analysis of 741 cases]. / Hemorragia digestiva superior. Analisis prospectivo de 741 casos.

A prospective study was performed to evaluate the epidemiological characteristics and clinical outcome of patients with upper digestive bleeding. Between April 1987 and May 1993, 741 patients, 517 men and 224 women, with a mean age of 50.48 years (range, 12 to 94) were admitted to the emergency department with this diagnosis. The chief complaint was tarry stool (88.4%). A total of 717 patients underwent endoscopic examination within a mean time of 17.2 hours of arrival at the emergency department. Duodenal ulcers were found in 216 (35.9%) patients, gastric ulcer in 240 (32.4%), gastritis in 74 (10%), esophageal varices in 38 (5.1%), and other causes in 121 patients (16.5%). 478 required blood transfusion (range of 1 to 15 blood units transfused). 80.4% of patients who died necessitated transfusion versus 62.5% of the patients who had a satisfactory outcome. A total of 672 cases (92%) were managed with medical therapy. In 90 cases (12.2%) endoscopic injection treatment with 75% alcohol was performed. 60 patients (8.18%) had surgical therapy, 81.7% of whom underwent emergency operation to arrest bleeding. The global mortality was 10.6% (78 of 741 patients), compared to 18.3% in patients who were operated. The highest mortality occurred in patients with esophageal varices. We conclude that peptic ulcer is still the mayor cause of upper digestive bleeding. The high mortality found in patients who required surgical therapy creates the need to select those patients who may get benefits of alternate therapies which may improve the outcome.